SEC Filing Summary: AntriaBio, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AntriaBio, Inc. on April 2, 2014. The registrant is incorporated in Delaware with principal executive offices in Menlo Park, California. The filing serves as a Regulation FD disclosure regarding a press release issued on the same date.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural report referencing an external press release (Exhibit 99.1) rather than a financial statement.
Material Changes
No material financial changes or comparative period data are disclosed within the body of this filing. The report solely indicates the issuance of a press release.
Guidance, Outlook, and Risks
The filing explicitly states that the information contained in the referenced press release is "furnished" and not "filed" for purposes of the Securities Exchange Act of 1934. Consequently, the text does not contain management commentary, guidance, risk factors, or details on contingencies. The content of the press release is not included in the provided source text.
Key Facts for Investor Verification
- Company Name Discrepancy: The request metadata lists "Rezolute, Inc.," but the filing is for "AntriaBio, Inc." Investors should verify if these entities are related or if the metadata is incorrect.
- Missing Content: The actual content of the press release (Exhibit 99.1) referenced in Item 7.01 is not included in the provided text; investors must locate the separate press release to understand the disclosed event.
- Legal Status: The information is deemed "furnished" under Regulation FD, meaning it is not subject to the same liability standards as "filed" information under the Exchange Act.
- Signatory: The report was signed by Nevan Elam, Chief Executive Officer and Chairman of the Board.